These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 19231329)

  • 1. Value of drug-eluting stents in cardiac transplant recipients.
    Gupta A; Mancini D; Kirtane AJ; Kaple RK; Apfelbaum MA; Kodali SK; Marboe C; Leon MB; Moses JW; Rabbani LE
    Am J Cardiol; 2009 Mar; 103(5):659-62. PubMed ID: 19231329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (> or =3.5 mm) coronary arteries.
    Steinberg DH; Mishra S; Javaid A; Slottow TL; Buch AN; Roy P; Okabe T; Smith KA; Torguson R; Xue Z; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Mar; 99(5):599-602. PubMed ID: 17317356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-based outcomes in percutaneous coronary intervention with drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry).
    Abbott JD; Vlachos HA; Selzer F; Sharaf BL; Holper E; Glaser R; Jacobs AK; Williams DO;
    Am J Cardiol; 2007 Mar; 99(5):626-31. PubMed ID: 17317361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous coronary interventions with stents in cardiac transplant recipients.
    Bader FM; Kfoury AG; Gilbert EM; Barry WH; Humayun N; Hagan ME; Thomas H; Renlund D
    J Heart Lung Transplant; 2006 Mar; 25(3):298-301. PubMed ID: 16507423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year clinical outcome with drug-eluting stents versus bare-metal stents in a real-world registry of unprotected left main coronary artery stenosis from the Italian Society of Invasive Cardiology.
    Palmerini T; Marzocchi A; Tamburino C; Sheiban I; Margheri M; Vecchi G; Sangiorgi G; Santarelli A; Bartorelli A; Briguori C; Vignali L; Di Pede F; Ramondo A; Inglese L; De Carlo M; Bolognese L; Benassi A; Palmieri C; Filippone V; Sangiorgi D; De Servi S
    Am J Cardiol; 2008 Dec; 102(11):1463-8. PubMed ID: 19026296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of outcomes using bare metal versus drug-eluting stents in coronary artery disease patients with and without human immunodeficiency virus infection.
    Ren X; Trilesskaya M; Kwan DM; Nguyen K; Shaw RE; Hui PY
    Am J Cardiol; 2009 Jul; 104(2):216-22. PubMed ID: 19576350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-stenosis after drug-eluting stents in cardiac allograft vasculopathy.
    Aqel RA; Wells BJ; Hage FG; Tallaj J; Benza R; Pamboukian S; Rayburn B; McGiffin D; Kirklin J; Bourge R
    J Heart Lung Transplant; 2008 Jun; 27(6):610-5. PubMed ID: 18503959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    Lee CW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Yun SC; Seong IW; Lee JH; Lee NH; Cho YH; Cheong SS; Lim DS; Yang JY; Lee SG; Kim KS; Yoon J; Jeong MH; Seung KB; Hong TJ; Park SJ;
    Am J Cardiol; 2009 Nov; 104(10):1370-6. PubMed ID: 19892052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution.
    Li Y; Zheng Z; Xu B; Zhang S; Li W; Gao R; Hu S
    Circulation; 2009 Apr; 119(15):2040-50. PubMed ID: 19349321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
    Kaltoft A; Jensen LO; Maeng M; Tilsted HH; Thayssen P; Bøttcher M; Lassen JF; Krusell LR; Rasmussen K; Hansen KN; Pedersen L; Johnsen SP; Sørensen HT; Thuesen L
    J Am Coll Cardiol; 2009 Feb; 53(8):658-64. PubMed ID: 19232897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of coronary stent thrombosis based on academic research consortium definitions.
    Applegate RJ; Sacrinty MT; Little WC; Santos RM; Gandhi SK; Kutcher MA
    Am J Cardiol; 2008 Sep; 102(6):683-8. PubMed ID: 18773988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow-up results from a large single-center database.
    Liu HB; Xu B; Yang YJ; Wang Y; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Ma WH; Li JJ; Qiao SB; Chen JL; Li W; Gao RL
    Chin Med J (Engl); 2009 Mar; 122(6):681-6. PubMed ID: 19323934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous coronary intervention using drug-eluting stents in pediatric heart transplant recipients.
    Sachdeva R; Seib PM; Frazier EA; Sachdeva R
    Pediatr Transplant; 2009 Dec; 13(8):1014-9. PubMed ID: 19207219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation.
    Ota T; Umeda H; Yokota S; Miyata S; Takamura A; Sugino S; Hayashi K; Ishiki R; Takeichi Y; Iwase M; Inagaki H; Murohara T
    Am Heart J; 2009 Jul; 158(1):92-8. PubMed ID: 19540397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.